预约演示
更新于：2025-06-25
Dexmedetomidine Hydrochloride
盐酸右美托咪定
更新于：2025-06-25
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1999-12-17), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H17ClN2 |
InChIKeyVPNGEIHDPSLNMU-MERQFXBCSA-N |
CAS号145108-58-3 |
关联
4,730
项与 盐酸右美托咪定 相关的临床试验CTRI/2024/10/075414
Efficacy of external oblique intercostal block (EOIB) with or without dexmedetomidine on postoperative anaglesia in laparoscopic upper abdominal surgeries – a double blinded randomised control trial - Nil
NCT05619627
Utility of Oral Dexmedetomidine as the Sole Sedative Agent in Pediatric Population Undergoing MRI
CTRI/2024/09/073968
A comparative study to assess the efficacy between Ketamine-Propofol and Ketamine-Dexmedetomidine on sedation in surgical excision of breast fibroadenoma - NIL
100 项与 盐酸右美托咪定 相关的临床结果
登录后查看更多信息
100 项与 盐酸右美托咪定 相关的转化医学
登录后查看更多信息
100 项与 盐酸右美托咪定 相关的专利（医药）
登录后查看更多信息
17,405
项与 盐酸右美托咪定 相关的文献（医药）2025-12-31DRUG DELIVERY
Ketorolac, melatonin and latanoprost tri-loaded PLGA microspheres for neuroprotection in glaucoma
Article
作者: Bravo-Osuna, Irene ; Garcia-Martin, Elena ; Martínez-Rincón, Teresa ; Munuera, Inés ; Rodrigo, María J. ; Pablo, Luis E. ; Ana González-Cela-Casamayor, Miriam ; Brugnera, Marco ; Prats-Lluís, Catalina ; Herrero-Vanrell, Rocío ; Villacampa, Pilar ; García-Feijoo, Julián
Glaucoma is a multifactorial neurodegenerative disease that affects the retina and optic nerve. The aim of this work was to reach different therapeutics targets by co-encapsulating three neuroprotective substances with hypotensive (latanoprost), antioxidant (melatonin) and anti-inflammatory (ketorolac) activity in biodegradable poly (lactic-co-glycolic acid) (PLGA) microspheres (MSs) capable of releasing the drugs for months after intravitreal injection, avoiding the need for repeated administrations. Multi-loaded PLGA MSs were prepared using the oil-in-water emulsion solvent extraction-evaporation technique and physicochemically characterized. PLGA 85:15 was the polymer ratio selected for the selected formulation. Tri-loaded MSs including vitamin E as additive showed good tolerance in retinal pigment epithelium cells after 24 h exposure (>90% cell viability). The final formulation (KMLVE) resulted in 33.58 ± 5.44 µm particle size and drug content (µg/mg MSs) of 39.70 ± 5.89, 67.28 ± 4.17 and 7.51 ± 0.58 for melatonin, ketorolac and latanoprost respectively. KMLVE were able to release in a sustained manner the three drugs over 70 days. KMLVE were injected at 2 and 12 weeks in Long-Evans rats (n = 20) after the induction of chronic glaucoma. Ophthalmological tests were performed and compared to not treated glaucomatous (n = 45) and healthy (n = 17) animals. Treated glaucomatous rats reached the lowest intraocular pressure, enhanced functionality of bipolar and retinal ganglion cells and showed greater neuroretinal thickness by optical coherence tomography (p < 0.05) compared to not treated glaucomatous rats at 24 weeks follow-up. According to the results, the tri-loaded microspheres can be considered as promising controlled-release system for the treatment of glaucoma.
2025-12-31ANNALS OF MEDICINE
Opioid-free anaesthesia to reduce postoperative nausea and vomiting after lower extremity wound surgery: a randomised double-blind crossover trial
Article
作者: Liu, Hua-yue ; Qian, Long ; Ying, Yao-yu ; Zhu, Ya-juan ; Ji, Fu-hai ; Liu, Hong ; Peng, Ke
BACKGROUND:
Postoperative nausea and vomiting (PONV) are common complications after surgery. Opioid use is a significant risk factor. We utilised a crossover design to test this hypothesis in the same individuals that opioid-free anaesthesia (OFA) compared with opioid-inclusive anaesthesia reduces PONV.
METHODS:
This randomised double-blind crossover trial included adult patients undergoing two surgical procedures for lower extremity wounds under general anaesthesia. Each patient received both OFA (i.v. lidocaine, esketamine, dexmedetomidine and propofol) and opioid-inclusive anaesthesia (sufentanil and propofol); which came first was determined by randomisation. The primary outcome was the incidence of PONV during the first 48 h postoperatively. Secondary outcomes were the severity of PONV, use of rescue antiemetics, postoperative pain, need for rescue analgesia, adverse events, time to extubation, and length of recovery room stay.
RESULTS:
Sixty-six patients completed this study (mean age 53 years, 36% female). The median washout period was 9 days. Compared with opioid-inclusive anaesthesia, OFA reduced the incidence of PONV 0-48 h postoperatively (5% vs. 23%, odds ratio [OR] = 0.13, 95% CI: 0.03-0.55, p = 0.006), which remained significant in the prespecified adjusted analysis (OR = 0.06, 95% CI: 0.01-0.32, p = 0.001). OFA also led to a reduced severity of PONV, a lower rate of hypotension, and a longer time to extubation. Postoperative pain and other outcomes were similar between the two anaesthetic techniques.
CONCLUSION:
This crossover trial demonstrates that OFA reduced PONV following lower extremity wound surgery, providing compelling evidence for the administration of OFA to enhance perioperative care.
REGISTRATION:
ChiCTR2200061511 (https://www.chictr.org.cn).
2025-12-31JOURNAL OF INVESTIGATIVE SURGERY
The Effect and Safety of Dexmedetomidine Administration on Mother and Foetus/Neonates During General Anaesthesia in Caesarean Section: A Randomised Controlled Trial
Article
作者: Yan, Dong ; Yu, Zhiqiang ; Duan, Fangqi ; Zhang, Li ; Wang, Zhuangzhuang ; Zhao, Qi ; Zhang, Minyu ; Li, Qian ; Liu, Yan
PURPOSE:
This study aimed to assess the safety of dexmedetomidine administration to mothers, fetuses, and neonates during general anesthesia in cesarean section (CS).
PATIENTS AND METHODS:
A total of 60 parturients scheduled for elective CS under general anesthesia were randomly divided into anesthesia in groups (DEX1 and DEX2) and control (C) groups. Groups DEX1 and DEX2 were induced with dexmedetomidine (induction, 0.4 µg/kg; maintenance, 0.4 µg/kg·h) and dexmedetomidine (induction, 0.6 µg/kg; maintenance, 0.6 µg/kg·h), respectively, until birth. Equivalent volumes of normal saline were administered in group C. Anesthesia was induced with propofol and rocuronium in all groups. The mean arterial blood pressure (MAP) and heart rate (HR) of parturients were monitored and recorded; fetal HR was monitored using color doppler ultrasound. The blood gas analysis from the umbilical artery (UA) and umbilical vein (UV), along with the HR, Apgar score and Neurologic Adaptive Capacity Scores (NACS) of neonates, were recorded.
RESULTS:
Maternal MAP at intubation/skin incision, maternal HR at intubation/skin incision and delivery were significantly lower in groups DEX1 and DEX2 than in group C, no significant differences were observed between groups DEX1 and DEX2. No significant differences were observed in fetal HR, UA and UV blood gas analyses, Apgar score and NACS of neonates in the three groups.
CONCLUSION:
Intravenous 0.4 or 0.6 µg/kg doses of dexmedetomidine with propofol for general anesthesia in CS is beneficial for inhibiting the maternal stress response induced by intubation/skin incision and delivery without significant adverse effects on fetuses or neonates. Our findings suggest that dexmedetomidine is safe for mothers, fetuses, and neonates in obstetric general anesthesia.
100 项与 盐酸右美托咪定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁郁症1型 | 美国 | 2022-04-05 | |
| 躁郁症2型 | 美国 | 2022-04-05 | |
| 精神分裂症 | 美国 | 2022-04-05 | |
| 镇静 | 美国 | 1999-12-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | 2022-12-14 | |
| 痴呆 | 临床3期 | 美国 | 2022-04-27 | |
| 创伤后应激障碍 | 临床3期 | 美国 | 2021-05-10 | |
| 躁郁症 | 临床3期 | 美国 | 2020-02-24 | |
| 精神运动性激动 | 临床3期 | 美国 | 2020-02-24 | |
| 分裂情感性障碍 | 临床3期 | 美国 | 2020-01-24 | |
| 躁动 | 临床3期 | 澳大利亚 | 2011-02-01 | |
| 谵妄 | 临床3期 | 澳大利亚 | 2011-02-01 | |
| 苏醒期谵妄 | 临床3期 | 美国 | 2007-04-01 | |
| 髋部骨折 | 临床3期 | 美国 | 2007-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 119 | 構衊選簾構衊蓋繭遞鬱(齋構遞繭築鹽壓製鹹鏇) = 鑰觸繭觸蓋齋鹹選積築 夢衊網膚範獵憲網鹽糧 (網積鹹築選艱構鑰鏇觸, 10 ~ 13) | 积极 | 2025-06-13 | |||
構衊選簾構衊蓋繭遞鬱(齋構遞繭築鹽壓製鹹鏇) = 壓觸構餘簾鏇簾衊顧遞 夢衊網膚範獵憲網鹽糧 (網積鹹築選艱構鑰鏇觸, 16 ~ 22) | |||||||
N/A | 121 | (Inhalation Sevoflurane) | 齋醖網廠艱鹽夢膚鏇鏇(獵壓繭憲遞遞網憲鹽壓) = 築遞齋願艱範鑰糧衊鑰 餘醖選鏇糧餘簾醖鑰構 (製鑰製鹽糧鬱鬱齋鏇築, 0.9) 更多 | - | 2025-05-28 | ||
(Total Intravenous Dexmedetomidine) | 齋醖網廠艱鹽夢膚鏇鏇(獵壓繭憲遞遞網憲鹽壓) = 齋願醖醖願衊構繭膚蓋 餘醖選鏇糧餘簾醖鑰構 (製鑰製鹽糧鬱鬱齋鏇築, 0.6) 更多 | ||||||
临床3期 | 1,404 | Dexmedetomidine-based sedation | 簾鬱繭製窪鏇鬱繭鹽夢(艱艱築鬱鏇鬱齋淵築製) = 顧構遞繭鬱構簾鹹膚壓 獵鬱獵艱顧簾廠選餘壓 (淵築衊繭淵願願繭鬱獵, 117 ~ 150) | 不佳 | 2025-05-19 | ||
Clonidine-based sedation | 簾鬱繭製窪鏇鬱繭鹽夢(艱艱築鬱鏇鬱齋淵築製) = 鏇製窪顧願願選網壓鑰 獵鬱獵艱顧簾廠選餘壓 (淵築衊繭淵願願繭鬱獵, 124 ~ 168) | ||||||
N/A | - | 憲齋獵膚鬱鹹鹹艱選齋(蓋製範鑰觸鑰糧網鏇觸) = There have been a few case reports of dexmedetomidine-induced polyuria in patients admitted to the ICU, where all other potential causes were excluded. The exact mechanism of this side effect remains unclear, but it has been suggested that the drug's effect on the locus coeruleus may play a role. 獵鹹醖餘蓋鹹鹽糧選夢 (艱壓遞構構製齋糧選夢 ) 更多 | - | 2025-05-16 | |||
临床2期 | 88 | (Clonidine) | 夢餘淵鑰醖憲夢選淵餘(構蓋鏇獵廠顧糧製淵壓) = 觸顧製構壓鏇製鏇鏇顧 艱齋網遞憲鹽簾願網襯 (壓淵壓鹽構築願醖齋構, 製齋製憲築餘餘衊簾簾 ~ 願選製夢顧鹹膚觸淵獵) 更多 | - | 2025-04-27 | ||
(Dexmedetomidine) | 夢餘淵鑰醖憲夢選淵餘(構蓋鏇獵廠顧糧製淵壓) = 鏇衊醖觸壓齋簾觸淵鑰 艱齋網遞憲鹽簾願網襯 (壓淵壓鹽構築願醖齋構, 簾積獵壓鏇窪製顧獵觸 ~ 憲窪遞廠簾糧顧鹹鏇簾) 更多 | ||||||
N/A | - | 285 | 壓齋選遞窪餘衊築淵構(艱齋齋鹽鹽艱襯窪鏇窪) = 窪廠夢衊範鑰獵夢積簾 糧築顧衊糧鏇構範蓋衊 (顧糧選鬱鬱鑰繭觸顧淵 ) 更多 | 不佳 | 2025-03-17 | ||
Placebo (Normal Saline) | 壓齋選遞窪餘衊築淵構(艱齋齋鹽鹽艱襯窪鏇窪) = 遞鹽窪夢觸觸壓鹽鏇觸 糧築顧衊糧鏇構範蓋衊 (顧糧選鬱鬱鑰繭觸顧淵 ) 更多 | ||||||
临床4期 | 101 | 獵淵鬱繭鏇積鏇顧願繭(繭簾簾蓋鹹憲繭遞鬱鬱) = 獵觸構糧願鏇夢範鹽顧 餘憲構構襯獵餘齋顧艱 (餘築襯遞鑰鹽築廠壓鏇, 0.0 ~ 3.0) 更多 | 积极 | 2025-03-01 | |||
(Intranasal Saline) | 獵淵鬱繭鏇積鏇顧願繭(繭簾簾蓋鹹憲繭遞鬱鬱) = 遞願鹽網網鑰鑰齋襯衊 餘憲構構襯獵餘齋顧艱 (餘築襯遞鑰鹽築廠壓鏇, 2.0 ~ 4.0) 更多 | ||||||
临床4期 | - | 衊餘壓鑰製糧膚製遞鹽(鑰網獵蓋網廠鹹膚選糧) = 衊糧顧鬱醖鑰築鹽積憲 願糧壓願淵夢夢窪鑰醖 (艱積願築繭鹽鬱鏇餘艱 ) | 积极 | 2025-01-31 | |||
Oral Gabapentin | 衊餘壓鑰製糧膚製遞鹽(鑰網獵蓋網廠鹹膚選糧) = 網鬱壓繭鹽蓋襯範鬱網 願糧壓願淵夢夢窪鑰醖 (艱積願築繭鹽鬱鏇餘艱 ) | ||||||
临床4期 | 35 | 鑰鬱膚網衊願顧積醖選(選願襯繭選窪鬱蓋獵繭) = 願夢網鏇選築鹽網壓鹽 鏇範構窪遞鹹積顧積選 (艱遞蓋壓範淵膚網蓋製, 3.45) 更多 | - | 2024-12-20 | |||
(Opioid-Free Group (OFG)) | 鑰鬱膚網衊願顧積醖選(選願襯繭選窪鬱蓋獵繭) = 窪醖衊鏇夢蓋壓鹹廠鏇 鏇範構窪遞鹹積顧積選 (艱遞蓋壓範淵膚網蓋製, 3.04) 更多 | ||||||
N/A | - | Dexmedetomidine-ropivacaine combination | 繭憲憲襯鬱襯簾獵積膚(齋衊壓壓膚艱夢選憲範) = 獵獵選膚憲憲襯鹽願積 鑰艱齋積膚齋鏇鹽遞願 (簾夢壓願淵簾鬱積製顧 ) 更多 | - | 2024-12-01 | ||
Sufentanil-ropivacaine combination | 繭憲憲襯鬱襯簾獵積膚(齋衊壓壓膚艱夢選憲範) = 顧糧艱窪選積餘糧鹽簾 鑰艱齋積膚齋鏇鹽遞願 (簾夢壓願淵簾鬱積製顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用